Article Text

Download PDFPDF
BRCA Germline Mutations in Women With Uterine Serous Carcinoma-Still a Debate
  1. Ofer Lavie, MD*,
  2. Alon Ben-Arie, MD,
  3. Yakir Segev, MD*,
  4. Jonathan Faro, BSc*,
  5. Frida Barak, MD,
  6. Nir Haya, MD*,
  7. Ron Auslender, MD* and
  8. Ofer Gemer, MD
  1. * From the Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa;
  2. Kaplan Medical Center, Rehovot; and
  3. Barzilai Medical Center, Ashkelon, Israel.
  1. Address correspondence and reprint requests to Ofer Lavie, MD, Gyn-Oncology Unit, Carmel Medical Center, 7 Michal St, Haifa 34362, Israel. E-mail: olavie{at}


Objective: To determine the incidence of BRCA1 and BRCA2 mutations in an enlarged series of uterine serous carcinoma (USC) patients and to determine whether patients with USC are associated with a personal or familial history of breast or ovarian carcinoma.

Methods: A cohort of all consecutive patients with diagnosed USC was identified for 9 years. Family pedigrees were drawn as far back and laterally as possible. In all patients, genomic DNA was extracted from peripheral blood samples and analyzed for the 3 mutations common in Ashkenazi Jewish patients. All patients went through total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Tubal, ovarian, and peritoneal carcinoma were ruled out clinically and pathologically in all patients.

Results: Of 51 consecutive patients with USC in Ashkenazi Jews studied, we identified 13 patients (25.5%) who were previously found to have breast carcinoma, 17 patients (33.3%) who had a first-degree relative with breast or ovarian carcinoma, and 8 patients (15.7%) who were found to be carriers of 1 of the 3 BRCA germline mutations.

Conclusions: This series of USC patients, the largest consecutive series to date, suggests a higher incidence of BRCA carriers among Ashkenazi Jews as compared with the general population. This high rate of BRCA germline mutations in USC patients coupled with a high rate of personal and familial cancer histories may suggest that USC is associated with the hereditary breast-ovarian syndrome. This potential association of USC to the BRCA-associated cancer spectrum may have implications for the clinical management and intervention of unaffected BRCA1-2 germline mutation carriers. However, at the current time, there are insufficient data to provide evidence-based guidelines regarding the optimal timing or specific intervention to prevent cancers in these high-risk women.

  • BRCA
  • Uterine serous carcinoma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare that there are no conflicts of interest.